When Lawrence Cullen discusses Supplementary Protection Certificates (SPCs[i]), he does so with the clarity and passion of someone who has spent decades at the heart of the system—and who still finds it intellectually rewarding. After a distinguished career at the UK Intellectual Property Office (UKIPO), where he became one of the UK’s leading experts on SPCs, Lawrence has launched a consultancy to help others navigate the intricacies of life sciences IP.
From Chemistry Labs to IP Policy
Lawrence’s journey into IP began in the lab. Originally from Ireland, he studied industrial chemistry there at the University of Limerick. He then went on to complete a PhD at the University of Sheffield. A research career followed, taking him to UK. France, Germany, and the United States. It was during this time—working on a some patents at the University of Kentucky—that his interest in IP was sparked.
“I read my original proposal to the university for the patent and then saw the final patent application,” he recalls. “They were both describing the same thing but in completely different ways. I found that transformation fascinating.”
After returning to the UK with a young family and looking for a more stable career path, Lawrence applied to the UKIPO—and never looked back.
Building a Reputation in SPCs
Lawrence spent just under three decades at the UKIPO. Initially as a patent examiner, then working in policy and trademarks en route to becoming a Deputy Director and Hearing Officer in patents. His experience spans petrochemicals, cosmetics. pharmaceuticals and biotech, but it’s his specialism in SPCs that has become his hallmark.
“What makes SPCs so challenging is that they sit at the intersection of patent law and regulatory law,” he explains. “They’re not just a patent extension. They’re a sui generis right—unique in legal terms—and require a good understanding of both systems.”
As a Hearing Officer, Lawrence was responsible for reviewing disputed SPC applications. He often found himself deciding issues involving the UK’s approach to SPC case law for the first time. His decisions, nearly all of which were appealed (and subsequently upheld) helped clarify regulatory grey areas and provided vital guidance in a field where every word of the relevant legislation is scrutinised.
“It is not surprising that these decisions were nearly always appealed” he says “given the commercial value of the right being sought. Aa single granted SPC could be worth millions. That’s why nearly every one of the 19 articles in the relevant regulation has been argued over and litigated!”
A New Consultancy for a Complex Landscape
Now, Lawrence is offering his specialist knowledge directly to clients through his new consultancy. His goal? To support life sciences businesses, patent attorneys, and legal teams as they deal with complex SPC and pharmaceutical patent issues.
“If someone comes to me and asks, ‘Can I get an SPC based on this patent and this marketing authorisation?’ I can help them assess the options—perhaps even identify strategies they hadn’t considered.”
His expertise is particularly valuable at critical decision points: choosing the right patent to base an SPC on, assessing post-grant amendment possibilities, and anticipating how a granting authority might interpret a borderline case.
“Most people only apply for one SPC in a given matter, so there’s a lot riding on getting it right,” he adds. “My job is to bring clarity and reduce uncertainty.”
Beyond the Patent Office
Lawrence’s consultancy work is already expanding. He supports clients with early-stage planning, responds to refusals, and even helps those opposing SPCs in competitive scenarios. He’s also involved in academic research as a Visiting Scholar at the University of Sheffield, exploring the foundations and future of the SPC system.
His aim is to ensure that clients not only understand how the system works today but are also prepared for the changes ahead.
“We’re entering a more complex regulatory environment—particularly with medical devices and software becoming integral to treatments. That’s going to create new questions around if and how SPCs apply.”
Still Curious, Still Learning
Despite decades in the field, Lawrence’s enthusiasm remains undimmed.
“Every problem is slightly different. I still enjoy the ambiguity. You’re often working on the balance of probabilities, not certainties. That keeps it fresh.”
That curiosity extends beyond the office. When not immersed in SPC regulations, Lawrence is likely to be out walking stretches of the Wales Coast Path. Or, cheering from the stands at rugby games. A recent trip to Australia for the British & Irish Lions tour being a particular highlight.
“Being there and seeing the games in person was incredible. I’ve played the game, coached it, and still find it endlessly fascinating.”
How Lawrence Can Help
If you’re navigating SPCs—whether preparing an application, managing a refusal, or just trying to understand your strategic options—Lawrence is ready to help. With in-dept knowledge of how decisions are made and why, his consultancy offers a rare depth of insight for those operating in the life sciences, pharmaceutical, and biotech sectors. To get in touch with Lawrence or learn more about his services, connect via LinkedIn
A Supplementary Protection Certificate (SPC) is an intellectual property right that extends the protection of a patented active ingredient in a pharmaceutical or plant protection product. SPCs compensate for the time it takes to obtain regulatory approval before a product can be sold, offering up to five additional years of market exclusivity after a patent expires. Because they sit at the intersection of patent and regulatory law, SPCs are both legally and commercially significant—yet often misunderstood. This article explores their impact and the unique expertise Lawrence Cullen brings to this space.
In the latest instalment of our Meet the IP Professional series, we spoke to Oliver Tidman, an Intellectual Property lawyer with a deep passion for brand protection and founder of Edinburgh-based law firm Tidman Legal. With a client-focused approach and a reputation for making IP law accessible, Oliver shared his journey into the world of trademarks, the challenges facing modern businesses, and why prevention truly is better than cure when it comes to protecting your brand.
A Natural Fit for Innovation and Identity
From early on in his legal career, Oliver was drawn to the intersection of law, innovation, and branding.
“I’ve always had an interest in the creative and commercial aspects of business and entrepreneurship — how ideas become valuable assets,” he explains. “Trademarks stood out because they’re so closely tied to a business’s identity and reputation. Helping people protect what makes their business unique felt like a natural fit.”
This focus on identity and growth led Oliver to establish Tidman Legal in 2017. Before founding his firm, he built experience both in private practice and in-house roles in Edinburgh and London, gaining valuable insights into how different organizations approach IP strategy.
Building a Client-Centred IP Practice
Tidman Legal has carved out a strong niche by offering clear, commercially-minded advice without unnecessary complexity. Whether supporting a startup registering its first trademark or guiding a business expanding overseas, Oliver and his team focus on aligning IP protection with long-term growth goals.
“We don’t just file trademarks—we help clients build IP strategies across trademarks, patents, designs and copyright. Everything is tailored to help move the business forward.”
Common Pitfalls and the Power of Early Action
When asked about the most frequent mistakes he sees among startups and SMEs, Oliver doesn’t hesitate:
“The biggest one? Launching a brand without properly checking if the name is available. Too often, businesses invest in branding, websites, and marketing—only to face opposition or be forced into a costly rebrand.”
To help businesses avoid this, Tidman Legal offers a free downloadable guide: “5 Pitfalls of Failing to Register a Trade Mark”5 Branding Pitfalls Guide.
He also stresses the importance of thinking globally from day one, especially for online businesses.
Navigating Disputes and Strategic Enforcement
Trademark disputes, Oliver says, require the foresight of a chess game.
“It’s not just about reacting to a move — it’s about anticipating the other side’s strategy and knowing when to push forward or negotiate.”
He recalls one case where a startup faced opposition from a multinational company. Through smart strategy and evidence gathering, they not only protected the application but secured a coexistence agreement. The win was not just in registration, it was in protecting future international growth.
IP in a Digital World
With brands increasingly operating across borders and platforms, enforcement is becoming more complex.
“Some countries allow swift enforcement, others are more drawn out. I’d like to see more action around bad faith filings — something similar to the process for the Uniform Domain Name Dispute Resolution Policy (UDRP), which is fast and cost-effective.”
AI and digital tools are also playing an increasing role in monitoring and clearance.
“We use AI-powered tools to monitor trade mark applications and alert clients to potential issues. But there’s still a vital role for human insight and strategic advice.”
Educating and Empowering Clients
Oliver is a strong advocate for IP education—especially for startups and small businesses.
“Often, clients don’t come to us until there’s already a dispute. In my experience, many of these clients don’t fully understand the value of their IP until there is already a dispute or infringement. By that point, they’re on the back foot having to deal with brand damage or even having to rebrand entirely. That’s why I strongly believe that prevention is always better than cure.”
Tidman Legal supports this through blog posts, webinars, and events to raise awareness and simplify complex IP topics.
Looking Ahead: Opportunities and Challenges
What’s next for trademarks?
“AI is accelerating brand creation. But with that speed comes risk — deepfakes, voice cloning, and auto-generated infringing content. It’s a challenging area that may need new legislation to keep pace.”
Oliver also highlights the need for better funding access for early-stage innovators.
“There is support out there, but the hurdles are often high. I’d like to see more funding aimed at startups, which often have limited resources, so they can access professional IP advice early on.”
Personal Reflections
What part of your work do you find most rewarding?
“Helping someone go from an idea sketched on a napkin to a protected brand on shelves or screens is incredibly satisfying. IP is intangible but its impact is very real – when a client sees their brand protected and they can grow with confidence, that’s the real payoff.”
What advice would you give to aspiring IP professionals who are particularly interested in working with trademarks?
“Start by developing commercial awareness as much as legal expertise. Brands live in the real world – they evolve, pivot and rebrand. Also, keep an eye on tech, it’s changing the IP landscape faster than legislation can.”
Beyond the Office
When he’s not helping clients protect their brands, you’ll often find Oliver on the squash court competing in the East of Scotland leagues. A recent highlight? A match against a former world No. 1.
“I only managed to get one point off him but it was a surreal experience!”
Oliver enjoys playing saxophone in his spare time and is also a keen hiker and recommends the Pentland Hills just outside Edinburgh:
“You get an incredible view across the city over to Fife.”
“Playing sax has a lot in common with IP law. In both worlds, timing is everything – whether you’re playing the right rhythm or filing a trademark before someone else does!”
P.S. PatWorld works with companies like Tidman Legal to deliver professional trademark, patent, and registered design searches. You can order a professional search directly through our website—trusted by IP professionals across the UK and beyond. https://patworld.com/us/order-a-search/
If you ask Stephen Mohun how he got into intellectual property, he’ll be the first to admit it wasn’t a lifelong calling. “I’m ashamed to say it was nothing more than a job advert,” he confesses with a laugh. But sometimes the best careers start with curiosity—and in Steve’s case, it sparked a lifelong passion for helping innovators protect and leverage their ideas.
Now the founder of Mohun Aldridge Sykes, Steve has spent nearly four decades advising clients on patents and trademarks, building a reputation for practical, strategic, and empathetic support—especially for those in the manufacturing and engineering sectors. His client base ranges from ambitious start-ups to global corporates, and his advice is always grounded in commercial reality.
“We always start with their bigger goals and work back from there. That’s how we build a real IP strategy—not just a filing plan.”
From Yorkshire Roots to Global Reach
Steve began his career at a local Yorkshire firm and worked his way through larger practices, eventually becoming a partner before founding the firm that became Mohun Aldridge Sykes. Launching his own boutique firm wasn’t just a career pivot—it was a chance to do things his way.
What sets Mohun Aldridge Sykes apart? It’s the depth of relationships. “We genuinely get to know our clients. We’re not just experts on the other end of the phone—we’re part of their strategic team.”
Intellectual Rigor, Commercial Focus
With a background in physics and a mind wired for problem-solving, it’s no surprise Steve is drawn to patent work. “I like understanding how things work,” he says. “Manufacturing clients, especially those in second or third-generation family businesses, are some of my favourites. They’re quietly innovating in ways they don’t always recognise.”
And that’s where Steve sees one of his biggest responsibilities: helping clients see the true value in their ideas. “Too many engineers dismiss their own work as ‘obvious.’ It’s our job to show them that what they’ve created might be valuable—and worthy of protection.”
Helping Clients Navigate Complexity
One of Steve’s great strengths is translating legal complexity into clear, actionable advice. “You have to put yourself in the client’s shoes. Legal jargon just puts up barriers. Our goal is to empower them.”
He’s particularly mindful of budget constraints for early-stage businesses. “The biggest mistake they make is spending too much too soon on the wrong things. We help them build a flexible, strategic IP plan that grows with them.”
A Trusted Partner in Innovation
Steve describes the ideal client relationship as one built on mutual trust. “They need to trust me to give honest, clear advice. And I need to trust that they’re telling me what’s really going on in the business.”
That trust has paid off—whether it’s guiding a manufacturing client into a leadership position through carefully managed IP, or helping a tech start-up secure patents in a notoriously difficult field. “That one surprised even me,” he says, recalling a breakthrough. “But we got there, and today those patents are their most valuable asset.”
Supporting the Next Generation
Mentorship matters to Steve. Mohun Aldridge Sykes welcomes interns and work experience students, giving them a real taste of the profession. “We’ve all had good careers in this field,” he says. “It’s important to put a bit back in.”
Staying Agile in a Changing Landscape
As AI and tech continue to reshape the IP world, Steve stays ahead by listening. “You’ve got to talk to people—clients, colleagues, other professionals—and keep your ear to the ground. The moment you stop adapting, you fall behind.”
His golden rule for entrepreneurs? Talk to your IP attorney early and often. “There’s no such thing as too early, but there’s definitely too late.”
Beyond the Office
When Steve isn’t advising clients or mentoring the next generation, you might find him on stage. A proud member of the Batley Gilbert and Sullivan Society, Steve regularly takes on leading roles—with his recent turn as the captain in H.M.S. Pinafore being a personal highlight. “Both my kids were on stage with me,” he smiles. “There’s nothing better than that.”
Get in Touch with Steve Mohun
With nearly four decades of experience in intellectual property, Stephen Mohun has built a reputation not just for legal precision, but for the kind of clear, trusted advice that clients remember. As founder of Mohun Aldridge Sykes, Steve blends technical expertise with commercial insight—helping innovators protect what matters and make confident decisions along the way.
How PatWorld Supports Firms Like Mohun Aldridge Sykes
At PatWorld, we understand that high-quality, professional patent searches are the foundation of strong IP advice. For firms like Mohun Aldridge Sykes—who focus on strategic guidance, commercial insight, and trusted relationships—our global patent search tools and analyst-led services offer an ideal complement. Whether it’s prior art, freedom-to-operate, or competitive intelligence, we help professionals like Steve deliver peace of mind to their clients with search services they can trust. Click for further information on PatWorld search services.
From diagnostics to cannabis-based therapeutics, Sophie Topham’s career in biotech patent law has been anything but predictable. A Senior Associate in the biotechnology team at Marks & Clerk, Sophie’s calm, analytical approach is matched by a refreshing curiosity—qualities that have made her an invaluable asset to clients and colleagues alike. We caught up with her to hear about her work, career path, and the rare case that led to one of her most widely read articles.
From Immunology to Innovation
Sophie’s current docket spans a broad range of biotechnology innovations. While she regularly works with immunology-based diagnostics and oncology-related inventions (including peptide vaccines and tools for identifying oncogenic mutations), her work is as diverse as the biotech field itself.
“Over the last few years, I’ve also worked in the cannabis field, particularly with extracts and synthetic cannabinoids for medical uses,” she explains. “And more recently, I’ve seen an increase in devices—some that resemble ELISAs on a chip, others that use antibodies in more novel ways.”
Despite the increasing overlap between biotech and AI, Sophie admits she still has a soft spot for what she calls “pure biology.” “As a biologist by training, those are the ones I find the most intuitive to work with.”
A Curious Case of Prior Art
In 2024, Sophie penned an article about an unusual and educational experience: having a client’s own clinical trial proposal cited as prior art against their European patent. It was the first time she’d encountered such a scenario—and it proved just as useful for the IP community as it did for her personally.
“Opponents in an EPO opposition cited the client’s trial proposal, which we hadn’t seen before due to a team change on the client’s side,” she recalls. “I had to dig into the case law to understand how such documents are interpreted, especially regarding whether the invention was truly disclosed.”
The case raised interesting questions around whether and how other documents—such as scientific publications—can be used to interpret clinical trial proposals, and how that squares with the EPO’s guidelines.
Understanding the Unusual
Sophie is quick to point out that having clinical trial proposals cited as prior art is still uncommon. “Patent applications in biotech typically don’t require clinical data to be granted. In vitro data is often sufficient for meeting plausibility requirements, so most companies file before trials begin,” she says.
Still, her experience highlighted how easy it is for assumptions to trip up even the most diligent teams. “We’ve seen clients express genuine surprise that their own publications can be cited against them—especially in Europe where there’s no grace period.”
The Route Not Taken
Like many in the IP profession, Sophie’s path wasn’t a straight line. “I originally wanted to be an airline pilot,” she laughs. “But when airlines stopped sponsoring training, the cost became unrealistic. Then I remembered a careers talk we had at university about being a patent attorney. I looked into it, and here I am.”
With a background in biological natural sciences from Cambridge, Sophie’s analytical mindset found a perfect home in IP law. She’s since seen applications through from drafting to grant, oppositions, and even appeals.
“Seeing something I’ve written be granted—and knowing I helped a startup gain recognition through their patent—those are the highlights,” she says.
Life Outside the Office
When she’s not deep in a patent claim, Sophie is rarely still. “I always try to move—walk, cycle, yoga, strength training. Even when working from home, I’ll build exercise into my day.” She’s part of a cycling club and makes time for a proper lunch break most days—usually with some kind of movement.
Evenings are more relaxed: cooking from scratch, reading anything from spy novels to translated Japanese fiction, and planning her next getaway. This summer, she’ll finally fulfil a childhood dream—horse riding along the beaches of Morocco with her twin sister.
If Only There Were More Hours…
When asked which fictional invention she’d most like to patent, Sophie doesn’t hesitate: “Hermione Granger’s Time-Turner. I’d love more hours in the day. If I knew how it worked, I’d make one!”
With her blend of sharp legal insight and grounded, genuine enthusiasm for the science behind the patents, Sophie brings a distinct human touch to biotech IP. Whether she’s tackling tricky prior art or galloping down a Moroccan beach, she’s doing it with purpose and passion.
Marks & Clerk is a leading international firm of intellectual property experts, providing comprehensive patent, trade mark, design, and litigation services. With a global presence and deep sector knowledge, Marks & Clerk supports innovative companies from startups to multinationals in protecting and leveraging their IP assets.
How PatWorld Supports Biotech Innovators
At PatWorld, we help biotech companies, attorneys, and researchers access fast, reliable, and intuitive global patent search tools. Our advanced search and analytics features enable professionals like Sophie to:
When it comes to securing exclusivity in the life sciences sector, few bring the depth of insight and strategic clarity that Francis Tierney offers. A qualified UK and European patent attorney since the 1990s, Francis blends decades of in-house experience with a boutique advisory approach that gives life sciences companies a genuine edge—particularly in pharmaceuticals and small molecule therapeutics. In this article PatWorld discusses with Francis Exclusivity in Pharma, and Navigating the Life Sciences Patent Landscape.
From In-House to Boutique: A Unique Perspective
Francis began his IP career in-house, spending nearly three decades advising on agrochemical and pharmaceutical innovations before moving into private practice. This “poacher turned gamekeeper” transition, as he jokingly puts it, equips him with an intuitive understanding of how clients operate and what they truly need from their IP counsel.
Now at Patent Boutique, he works closely with clients on prosecution, opposition, appeal work, due diligence, and strategic portfolio development. His tailored, hands-on approach is a hallmark of the firm.
The Five Pillars of Patent Strategy in Pharma
Francis sees five key IP considerations for life sciences companies today:
Confidentiality: With increased pressure to publish and attract investors, ensuring non-disclosure before filing is vital.
Timing of Filings: Filing too early can lead to protection ending earlier during peak sales; too late, and companies risk being scooped.
Collaboration with R&D: Patent attorneys need to work closely with research teams to react quickly to emerging data and shape strategy in real time.
Market Awareness: Limited budgets mean companies must prioritise filings in jurisdictions most critical to commercial success.
AI: Keeping abreast of developments in, and the increasing capabilities of, AI.
Getting Patent Drafting Right
Drafting for small molecules brings its own hazards. “If you draft too broadly, not only might your claims be rejected, but you risk creating your own most damaging prior art,” Francis warns. He emphasises the importance of including strong biological data—especially for markets like China—and ensuring that patents will remain enforceable 20+ years down the line, particularly when linked to SPCs.
US vs. Europe: Avoiding a Common Pitfall
One of the most frequent issues Francis sees is US-based companies underestimating global disclosure rules. “There’s a grace period in the US, but not in Europe. Smaller companies often publish during the priority year, which can be problematic for later filings,” he explains.
He also notes how different legal frameworks—such as the EPO’s problem-solution approach versus the US’s obviousness standard—can yield very different outcomes from the same prior art.
Early-Stage Advice: Flexible, Focused, and Fast
Emerging biotech companies often need more tailored support, especially when balancing speed, disclosure, and credibility for investors. Francis helps them navigate this by streamlining prosecution strategies and ensuring they have grantable, meaningful patents to support licensing or M&A activities.
“Established pharma companies have structured IP processes. Start-ups don’t—so we help them build systems and strategies that are credible and cost-effective,” he says.
Patent Portfolios as Deal Enablers
Whether supporting collaborations or preparing for acquisition, Francis views robust IP portfolios as central. “You need to show what you’ve got, but also what you might be developing. Priority filings before a deal are key to demonstrating value,” he advises.
AI in Drug Discovery: A New Frontier, with Caveats
Francis acknowledges AI as a potential game-changer in small molecule R&D, but with caution. “If AI knows everything, where’s the inventive step?” he asks. He sees a possible future where narrower, more focused patent claims become the norm due to more precise AI targeting—but also where validity could well be questioned if algorithms become standardised tools.
A Call for Change: Grace Period Reform
If he could change one thing in the UK or EU IP landscape, Francis would introduce a broader grace period. “It would protect researchers from the kind of accidental disclosures that can destroy patentability. A safety net—not to rely on, but to support honest mistakes.”
The Boutique Advantage
At Patent Boutique, Francis and his colleagues offer flexibility, cost transparency, and a collaborative approach. “We were cloud-based from the start, so our clients benefit from seamless document transfer, real-time communication, and scalable support,” he notes. Clients also gain access to a wider network of trusted attorneys—competency, not size or shine, is what counts.
Outside the Office: Gardening and Grandkids
Beyond the world of SPCs and claim drafting, Francis is a proud grandfather and a keen (and increasingly enthusiastic) gardener. “It’s such a contrast to patent law—where you wait years for a result. In the garden, you plant something and within weeks, there’s colour, texture, and reward,” he says. His latest pride? A set of stunning Alstroemeria —particularly a variety called Indian Summer.
Connect with Francis Tierney 🔗 Francis Tierney on LinkedIn 🔗 Patent Boutique – A specialist firm offering high-level, strategic patent services tailored to life sciences and beyond.
P.S. How PatWorld Supports Patent Attorneys Like Francis PatWorld supports IP professionals with expert-led Patent, Trademark, and Design Search services. Whether you’re advising clients on exclusivity strategies, preparing for prosecution or opposition, or managing complex portfolios, our tailored search solutions deliver the clarity and confidence you need to move forward.
From ballroom dancing and ten-pin bowling to guiding cutting-edge startups through the complexities of intellectual property, Andrew Flaxman has certainly had a diverse journey. Today, as a partner at Bristol-based IP firm Stevens Hewlett & Perkins (SH&P), Andrew is a passionate advocate for startups and a specialist in software, computing, and AI-related patents.
The Path to Patents
Andrew didn’t set out to become a patent attorney. In fact, it wasn’t until the final week of university that he picked up a leaflet that introduced him to the profession. With a love of physics, a knack for language, and a curiosity about the law, the role seemed like the perfect fit. He began his career in London before making the move to Bristol, eventually rising to partner level, and joining SH&P earlier this year.
A Day in the Life (Is Never the Same)
“There’s no typical day,” Andrew says. “I might be dealing with emails, drafting patents, speaking to clients, attending partner meetings, or at a conference. Every day brings something new.”
That dynamic workday is part of what makes the job so compelling—especially for someone who thrives on innovation and the unknown.
Championing Startups
Andrew’s enthusiasm shines when it comes to supporting early-stage ventures. He works closely with the SetSquared Bristol community and is especially proud of SH&P’s initiative Pitch and Protect, which awarded £10,000 in IP support to a start-up to help them get their first patent on file.
“Startups are looking for advisors who genuinely want to help,” he says. “We’re flexible and hands-on—being part of a firm that can adapt quickly is a real advantage.”
Debunking IP Myths
One of the most common misconceptions Andrew encounters? “Startups often think there’s no point in filing patents because they can’t afford to enforce them,” he explains. “But having IP can deter infringement and is a valuable business asset. It’s normally better to have rights than to have none at all.”
He also frequently hears from clients in computing and software who wrongly believe their ideas can’t be patented. “It’s a grey area, but certainly not impossible. I spend about 80% of my time working in this space. If in doubt, just have a conversation with a patent attorney.”
IP Trends and Tech Frontiers
Andrew is especially excited about the potential in robotics and automated systems—particularly when combined with AI.
“AI is already being used to help diagnose medical conditions, but we’re not far from seeing robotic surgery controlled by AI, even without a human surgeon. It’s incredible—and IP plays a crucial role in protecting that innovation.”
He’s also watching how generative AI is shaking up the IP profession itself. While some tools can assist with tasks like drafting, Andrew believes the nuance of legal language and strategic thinking still firmly requires a human touch.
Advice to Aspiring IP Professionals
“You need a strong technical foundation, but also great communication skills and an eye for detail,” he says. “So much of our work comes down to how we use words and what they mean.”
Keeping Skills Sharp
Andrew stays current the same way many of us do: reading articles, attending seminars, and yes—occasionally checking Wikipedia. “We learn a lot from our clients too,” he adds. “Conversations with inventors are often the best education.”
The Reward? Seeing Clients Succeed
“The most fulfilling part of my job is helping startups on their journey—from first filing to commercial success. You feel like part of the team, and their wins feel like your own.”
Fun Fact: From the Dance Floor to the Finish Line
Not many patent attorneys can say they were once a ballroom dancing champion, but Andrew can. Taught by his mother, he won several competitions as a child before trading dance shoes for rugby boots. He later became a ten-pin bowling champ, and today, he’s an Ironman triathlete who completed Ironman Wales and is training for his next race in Leeds.
If He Could Invent Anything…
“A time machine,” Andrew says without hesitation. “Not to go to the future, but to visit key moments in history—just to see what life was really like.”
PatWorld works with patent attorneys like Andrew to provide expert patent searching across all technology sectors. Whether you’re exploring an idea or protecting a breakthrough, our patent search reports helps professionals make informed IP decisions.
To find out how PatWorld can support your firm or in-house team, check out the links below or contact us directly on [email protected].
Embracing the Future: Anti-Aging Technology – The Senescence Revolution
The realm of anti-aging has been revolutionized by ground-breaking research and technology, a testament to human ingenuity and the relentless pursuit of longevity. A recent feature in the Women’s IP World Annual 2024, titled “Anti-Aging Technology – The Senescence Revolution,” penned by the innovative minds at PatWorld, casts a spotlight on the strides being made in this field.
Unveiling the Secrets of Senescence
Cellular senescence, a state where cells cease to divide yet remain metabolically active, plays a pivotal role in aging. The article delves into how understanding and manipulating this process can lead to significant anti-aging breakthroughs, promising a future where the effects of aging can be drastically mitigated.
Innovations at the Forefront
PatWorld’s experts provide an overview of the latest technologies and therapies that target cellular aging. These include genetic modifications, pharmaceutical interventions, and lifestyle changes that together form a comprehensive approach to extending the human health-span.
A Testament to Collaborative Genius
Highlighting the collaborative spirit within the scientific community, the article emphasizes the importance of shared knowledge and cross-disciplinary efforts in pushing the boundaries of what’s possible in anti-aging research.
Looking Ahead
The journey toward conquering aging is filled with challenges and opportunities. As we stand on the brink of a new era, the insights from “Anti-Aging Technology – The Senescence Revolution” not only inform but inspire continued exploration and innovation in the quest for longevity.
Chelsey Edwards – Patent Analyst at PatWorld on the Biotech team, specialising in Biotechnology, Medicine and Pharmaceuticals.
Chulin Dai – Senior Patent Analyst at PatWorld on the Chemistry team, specialising in Bio-Chemistry, Medicine and Pharmaceuticals.
Are you or your clients developing technologies in this critical area? Are you seeking support with IP Search Services or Patent Databases? If so, please click on the relevant links below.
If you enjoy our content here, you’ll love the stuff we share on LinkedIn, follow us now. However, if you’re not on LinkedIn, check out our other social media sites:
With 1 in 10 people living with Diabetes globally (537 million), and this is expected to rise to 643 million by 2030 and 783 million by 2045[i], finding new ways of preventing, diagnosing, and treating the disease is crucial. To celebrate World Diabetes Day 2023 we take a look at what innovations are being developed in the Health Technology sector relating to diabetes. To do this we initially ran a simple search on diabetes and isolated the search to the last five years publications only.
During this time, there have been almost 300k patent publications relating to Diabetes. As Figure 1 shows the patents are in a variety of classifications. However, almost a quarter of the publications relate to classification codes A61B5/145[ii] (Measuring Characteristics of Blood in Vito) and A61B5/00[iii] (Measuring for Diagnostic Purposes) and we will look at the innovators in this space and highlight a few of their patents.
Figure 1
Who are the main players in Diabetes Monitoring?
Figure 2 shows Roche, Dexcom, and Medtronic dominate, and we will showcase some of their recent patents.
Figure 2
Roche Diagnostics – Patent number US2020250939A1 MEDICAL DEVICE ALERT, OPTIMIZATION, PERSONALIZATION, AND ESCALATION
Figure 3 – Patent number US2020250939A1
This patent alerts the user via a message sent to their watch, smartphone, smart speaker, etc that their glucose levels have changed. The alerts will get progressively louder/stronger until the user acknowledges the message.
Dexcom – Patent number US2023138673A1 – RANKING FEEDBACK FOR IMPROVING DIABETES MANAGEMENT
Figure 4 Patent number US2023138673A1
This patent is a method for providing feedback based on glucose measurements. Readings are taken and analysed against historical data with alerts sent to the wearer advising if readings are higher/lower than normal at periodic times. Ways to make improvements are suggested if particular actions are taken, ie exercise activity.
Medtronic – Patent US2022143314A1 – DIABETES THERAPY BASED ON DETERMINATION OF FOOD ITEM
Figure 5 Patent number US2022143314A1
This patent by Medtronic discloses a method for adapting diabetes therapy based on what a person eats. Using a mixture of wearable devices and cameras, information is generated allowing therapy to be tailored to the individual based on their diet.
Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; {Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue}(measuring of blood pressure or blood flow A61B5/02; non-radiation detecting or locating of foreign bodies in blood A61B5/06)
Measuring for diagnostic purposes (radiation diagnosis A61B6/00; diagnosis by ultrasonic, sonic or infrasonic waves A61B8/00); Identification of persons
Are you developing new inventions around Diabetes?
At PatWorld, we understand the importance of protecting your #HealthTech inventions, and we can provide our clients with accurate, reliable, and cost-effective information and services tailored to meet individual needs.
Patent, Design, and Trademark Research Experts with a combined experience of over 200 years in Intellectual Property searching. Highly trained, dynamic in-house research teams specialising in a wide range of subject matter. All our analysts follow a training program developed by former IPO Examiners. Our teams are available to discuss any specific technical points regarding your search enquiries.
Order a Search Now